Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

LB-100

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Lixte Biotech, National Institute of Health and Medical Research

Drug class:

PP2A inhibitor

Related drugs:

‹

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	LB-100 Sensitive: D – Preclinical LB-100 Sensitive : D	LB-100 Sensitive: D – Preclinical LB-100 Sensitive : D
NPM-ALK fusion	Non-Hodgkin’s Lymphoma	NPM-ALK fusion	Non-Hodgkin’s Lymphoma	crizotinib + LB-100 Sensitive: D – Preclinical crizotinib + LB-100 Sensitive : D	crizotinib + LB-100 Sensitive: D – Preclinical crizotinib + LB-100 Sensitive : D
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	crizotinib + LB-100 Sensitive: D – Preclinical crizotinib + LB-100 Sensitive : D	crizotinib + LB-100 Sensitive: D – Preclinical crizotinib + LB-100 Sensitive : D